SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is indicated for:
Irrespective of gender only Adults (18 years old or older)
SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is contraindicated in the following cases:
Very rare cases of capillary leak syndrome (CLS) have been reported in the first days after vaccination with SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S), in some cases with a fatal outcome. A history of CLS has been reported. CLS is a rare disorder characterised by acute episodes of oedema mainly affecting the limbs, hypotension, haemoconcentration and hypoalbuminaemia. Patients with an acute episode of CLS following vaccination require prompt recognition and treatment. Intensive supportive therapy is usually warranted. Individuals with a known history of CLS should not be vaccinated with this vaccine.